Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 20 | 2019 | 334 | 2.780 |
Why?
|
| Anti-HIV Agents | 6 | 2017 | 50 | 1.290 |
Why?
|
| Continuity of Patient Care | 2 | 2019 | 64 | 0.670 |
Why?
|
| Homosexuality, Male | 6 | 2011 | 73 | 0.670 |
Why?
|
| Viral Load | 6 | 2018 | 64 | 0.620 |
Why?
|
| Rural Population | 4 | 2015 | 244 | 0.620 |
Why?
|
| HIV-1 | 3 | 2015 | 42 | 0.560 |
Why?
|
| Internet | 4 | 2011 | 156 | 0.520 |
Why?
|
| North Carolina | 13 | 2019 | 1422 | 0.480 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2017 | 28 | 0.470 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2012 | 21 | 0.440 |
Why?
|
| Community-Based Participatory Research | 4 | 2012 | 105 | 0.420 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2011 | 1 | 0.420 |
Why?
|
| Nitriles | 1 | 2011 | 22 | 0.410 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2011 | 16 | 0.410 |
Why?
|
| Pyrimidines | 1 | 2011 | 60 | 0.400 |
Why?
|
| Health Education | 2 | 2010 | 121 | 0.360 |
Why?
|
| Appointments and Schedules | 3 | 2019 | 16 | 0.360 |
Why?
|
| HIV | 2 | 2019 | 21 | 0.360 |
Why?
|
| Adult | 21 | 2019 | 8391 | 0.340 |
Why?
|
| Referral and Consultation | 2 | 2019 | 113 | 0.310 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2017 | 31 | 0.310 |
Why?
|
| Anti-Retroviral Agents | 1 | 2007 | 21 | 0.310 |
Why?
|
| Young Adult | 11 | 2019 | 2398 | 0.290 |
Why?
|
| Humans | 28 | 2019 | 29013 | 0.290 |
Why?
|
| Male | 24 | 2019 | 17768 | 0.270 |
Why?
|
| Ambulatory Care Facilities | 3 | 2019 | 63 | 0.220 |
Why?
|
| HIV Seropositivity | 2 | 2014 | 13 | 0.220 |
Why?
|
| Emigrants and Immigrants | 4 | 2012 | 235 | 0.210 |
Why?
|
| Middle Aged | 16 | 2019 | 10805 | 0.210 |
Why?
|
| Health Services Accessibility | 2 | 2015 | 231 | 0.200 |
Why?
|
| Female | 17 | 2019 | 18114 | 0.200 |
Why?
|
| Qualitative Research | 3 | 2019 | 142 | 0.200 |
Why?
|
| Patient Dropouts | 2 | 2019 | 24 | 0.190 |
Why?
|
| Medication Adherence | 2 | 2012 | 144 | 0.180 |
Why?
|
| Drug Therapy, Combination | 3 | 2015 | 273 | 0.180 |
Why?
|
| Hispanic Americans | 3 | 2012 | 904 | 0.180 |
Why?
|
| Directive Counseling | 1 | 2019 | 16 | 0.170 |
Why?
|
| Case Management | 1 | 2018 | 4 | 0.170 |
Why?
|
| Smoking Cessation | 1 | 2019 | 118 | 0.160 |
Why?
|
| Ambulatory Care | 1 | 2019 | 96 | 0.160 |
Why?
|
| Strongyloidiasis | 1 | 2017 | 3 | 0.160 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 17 | 0.160 |
Why?
|
| Treatment Outcome | 4 | 2015 | 3099 | 0.160 |
Why?
|
| Drug Administration Schedule | 3 | 2017 | 246 | 0.150 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2017 | 10 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2017 | 42 | 0.140 |
Why?
|
| Smoking | 1 | 2019 | 427 | 0.140 |
Why?
|
| Social Support | 2 | 2019 | 163 | 0.140 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2015 | 6 | 0.140 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2015 | 2 | 0.140 |
Why?
|
| Pyridazines | 1 | 2015 | 7 | 0.140 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 708 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 100 | 0.130 |
Why?
|
| Southeastern United States | 5 | 2014 | 71 | 0.130 |
Why?
|
| Risk-Taking | 3 | 2011 | 91 | 0.120 |
Why?
|
| Bone Density | 1 | 2015 | 182 | 0.120 |
Why?
|
| Pruritus | 1 | 2014 | 58 | 0.120 |
Why?
|
| Sexual Behavior | 2 | 2012 | 97 | 0.120 |
Why?
|
| Adolescent | 7 | 2019 | 3248 | 0.120 |
Why?
|
| Diffusion of Innovation | 1 | 2012 | 29 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 73 | 0.100 |
Why?
|
| Bisexuality | 2 | 2011 | 14 | 0.100 |
Why?
|
| Aged | 5 | 2014 | 9462 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2011 | 29 | 0.100 |
Why?
|
| Commerce | 1 | 2011 | 37 | 0.100 |
Why?
|
| Mexican Americans | 1 | 2012 | 58 | 0.100 |
Why?
|
| Safe Sex | 2 | 2009 | 14 | 0.100 |
Why?
|
| AIDS Serodiagnosis | 1 | 2011 | 4 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2015 | 1674 | 0.100 |
Why?
|
| Intention | 1 | 2011 | 27 | 0.100 |
Why?
|
| Sexual Partners | 2 | 2009 | 33 | 0.100 |
Why?
|
| Peer Group | 2 | 2010 | 41 | 0.100 |
Why?
|
| Time Factors | 2 | 2015 | 1997 | 0.090 |
Why?
|
| Community-Institutional Relations | 2 | 2007 | 18 | 0.090 |
Why?
|
| Focus Groups | 2 | 2007 | 103 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2009 | 49 | 0.090 |
Why?
|
| Heterosexuality | 1 | 2009 | 11 | 0.090 |
Why?
|
| Quality of Life | 1 | 2014 | 815 | 0.080 |
Why?
|
| Ritonavir | 1 | 2007 | 2 | 0.080 |
Why?
|
| Pyrimidinones | 1 | 2007 | 4 | 0.080 |
Why?
|
| African Americans | 1 | 2015 | 1373 | 0.080 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2007 | 3 | 0.080 |
Why?
|
| Condoms | 1 | 2007 | 35 | 0.080 |
Why?
|
| Methamphetamine | 1 | 2007 | 18 | 0.080 |
Why?
|
| Drug Resistance, Viral | 3 | 2015 | 10 | 0.080 |
Why?
|
| Morbidity | 1 | 2007 | 91 | 0.080 |
Why?
|
| Health Behavior | 1 | 2009 | 212 | 0.080 |
Why?
|
| Unsafe Sex | 1 | 2007 | 22 | 0.070 |
Why?
|
| Poverty | 1 | 2007 | 98 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 2106 | 0.070 |
Why?
|
| Emigration and Immigration | 1 | 2006 | 32 | 0.070 |
Why?
|
| Community Health Services | 1 | 2006 | 54 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2007 | 208 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2007 | 147 | 0.070 |
Why?
|
| Survival Rate | 1 | 2007 | 795 | 0.060 |
Why?
|
| Age Factors | 1 | 2007 | 1105 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2017 | 272 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2007 | 3712 | 0.040 |
Why?
|
| Counseling | 1 | 2019 | 85 | 0.040 |
Why?
|
| Substance-Related Disorders | 2 | 2012 | 109 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2011 | 469 | 0.040 |
Why?
|
| Telephone | 1 | 2018 | 48 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 175 | 0.040 |
Why?
|
| Strongyloides stercoralis | 1 | 2017 | 3 | 0.040 |
Why?
|
| Piperacillin | 1 | 2017 | 5 | 0.040 |
Why?
|
| Penicillanic Acid | 1 | 2017 | 5 | 0.040 |
Why?
|
| Antiparasitic Agents | 1 | 2017 | 6 | 0.040 |
Why?
|
| Klebsiella pneumoniae | 1 | 2017 | 7 | 0.040 |
Why?
|
| Ivermectin | 1 | 2017 | 9 | 0.040 |
Why?
|
| Patient Participation | 1 | 2018 | 62 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2017 | 78 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 43 | 0.040 |
Why?
|
| Bacteremia | 1 | 2017 | 53 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2014 | 1300 | 0.040 |
Why?
|
| Tuberculosis | 1 | 2017 | 14 | 0.040 |
Why?
|
| Australia | 1 | 2017 | 66 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 1353 | 0.040 |
Why?
|
| Mass Screening | 1 | 2019 | 223 | 0.040 |
Why?
|
| Pneumonia, Bacterial | 1 | 2017 | 31 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2007 | 636 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 159 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 284 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 706 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 129 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 185 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 197 | 0.030 |
Why?
|
| Psychological Theory | 1 | 2012 | 6 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2014 | 369 | 0.030 |
Why?
|
| Reproductive Health Services | 1 | 2012 | 5 | 0.030 |
Why?
|
| Consumer Health Information | 1 | 2011 | 6 | 0.030 |
Why?
|
| Risk Factors | 2 | 2012 | 3509 | 0.030 |
Why?
|
| Cultural Competency | 1 | 2011 | 16 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 892 | 0.020 |
Why?
|
| Motivation | 1 | 2012 | 102 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 863 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 385 | 0.020 |
Why?
|
| United States | 1 | 2019 | 3604 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 725 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2011 | 249 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 115 | 0.020 |
Why?
|
| Random Allocation | 1 | 2009 | 212 | 0.020 |
Why?
|
| HIV Protease Inhibitors | 1 | 2007 | 1 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 735 | 0.020 |
Why?
|
| Stereotyping | 1 | 2007 | 6 | 0.020 |
Why?
|
| Narration | 1 | 2007 | 10 | 0.020 |
Why?
|
| Videotape Recording | 1 | 2007 | 12 | 0.020 |
Why?
|
| Prejudice | 1 | 2007 | 45 | 0.020 |
Why?
|
| Students | 1 | 2009 | 167 | 0.020 |
Why?
|
| Spirituality | 1 | 2007 | 33 | 0.020 |
Why?
|
| Mutation | 1 | 2009 | 466 | 0.020 |
Why?
|
| Data Collection | 1 | 2007 | 163 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2007 | 119 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 7297 | 0.020 |
Why?
|
| Health Promotion | 1 | 2007 | 220 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2006 | 177 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2009 | 3107 | 0.010 |
Why?
|